Ireland - English - HPRA (Health Products Regulatory Authority)

bayer limited - calcium carbonate; magnesium carbonate; simeticone - chewable tablet - 680 mg/80 mg/25 milligram(s) - magnesium carbonate; calcium carbonate; antacids, other combinations; silicones

Ireland - English - HPRA (Health Products Regulatory Authority)

bayer limited - alginic acid; calcium carbonate; magnesium carbonate - chewable tablet - 625/73.5/150 milligram(s) - combinations and complexes of aluminium, calcium and magnesium compounds

United States - English - NLM (National Library of Medicine)

chang kuo chou pharmaceutical co. ltd. - magnesium carbonate (unii: 0e53j927na) (magnesium cation - unii:t6v3lhy838, carbonate ion - unii:7ujq5ope7d), sodium bicarbonate (unii: 8mdf5v39qo) (sodium cation - unii:lyr4m0nh37, bicarbonate ion - unii:hn1zra3q20) - magnesium carbonate 58 mg in 1 g - magnesium carbonate 58mg ................... antacid sodium bicarbonate 809mg .................... antacid - acid indigestion - heartburn - sour stomach - upset stomach from overindulgence in food or drink - symptoms persit or worsen antacid more than 6 capsules in a 24-hour period, or use the maximum dosage of this product for more than 2 weeks, expect under the advice and supervision of a physician. - presently taking a prescription drug.  antacid may interact with certain prescription drugs - on magnesium or sodium restrict diet.

United States - English - NLM (National Library of Medicine)

carilion materials management - magnesium carbonate (unii: 0e53j927na) (carbonate ion - unii:7ujq5ope7d), calcium carbonate (unii: h0g9379fgk) (calcium cation - unii:2m83c4r6zb), folic acid (unii: 935e97boy8) (folic acid - unii:935e97boy8) - magnesium carbonate 115 mg - patients who are hypermagnesemic or who have impaired renal function and are not being dialyzed should not be prescribed magnebind 400 rx.

United States - English - NLM (National Library of Medicine)

natural creations, inc. - magnesium carbonate (unii: 0e53j927na) (carbonate ion - unii:7ujq5ope7d), magnesium chloride (unii: 02f3473h9o) (magnesium cation - unii:t6v3lhy838), aesculus hippocastanum flower (unii: kk0z92ii8m) (aesculus hippocastanum flower - unii:kk0z92ii8m), potassium alum (unii: 1l24v9r23s) (aluminum hydroxide - unii:5qb0t2iun0), aluminum oxide (unii: lmi26o6933) (aluminum oxide - unii:lmi26o6933), bryonia alba root (unii: t7j046yi2b) (bryonia alba root - unii:t7j046yi2b), strychnos nux-vomica seed (unii: 269 - magnesium carbonate 3 [hp_x] in 1 ml - uses: temporarily relieves great straining, large, dry, hard, knotty stools, &/or other symptoms of constipation. uses: temporarily relieves great straining, large, dry, hard, knotty stools, &/or other symptoms of constipation.

United States - English - NLM (National Library of Medicine)

nephro-tech, inc. - magnesium carbonate (unii: 0e53j927na) (carbonate ion - unii:7ujq5ope7d), calcium carbonate (unii: h0g9379fgk) (carbonate ion - unii:7ujq5ope7d), folic acid (unii: 935e97boy8) (folic acid - unii:935e97boy8) - magnesium carbonate 115 mg - patients who are hypermagnesemic or who have impaired renal function and are not being dialyzed should not be prescribed magnebind 400 rx.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

thornton & ross ltd - magnesium trisilicate; magnesium carbonate light; sodium bicarbonate - oral suspension - 50mg/1ml ; 50mg/1ml ; 50mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

j m loveridge ltd - magnesium carbonate heavy - not applicable - 1mg/1mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

alliance healthcare (distribution) ltd - magnesium carbonate heavy - not applicable - 1mg/1mg

United States - English - NLM (National Library of Medicine)

wg critical care, llc - magnesium sulfate heptahydrate (unii: sk47b8698t) (magnesium cation - unii:t6v3lhy838) - magnesium sulfate heptahydrate 1 g in 100 ml - magnesium sulfate in 5% dextrose injection, usp is indicated for: magnesium sulfate in 5% dextrose injection is contraindicated in patients: risk summary magnesium sulfate in 5% dextrose injection is indicated in pregnant women for the prevention of eclampsia in women with preeclampsia and the treatment of seizures and prevention of recurrent seizures in women with eclampsia. fetal, neonatal, and maternal risks are discussed throughout the labeling. clinical considerations labor or delivery: magnesium sulfate in 5% dextrose injection is not approved for the treatment of pre-term labor. administration of magnesium sulfate in 5% dextrose injection to pregnant women longer than 5 to 7 days may lead to hypocalcemia and bone abnormalities in the developing fetus, including skeletal demineralization and osteopenia [see warnings and precautions (5.1)] . the use of intravenous magnesium in pregnant women increases human milk magnesium concentrations only slightly and oral absorption of magnesium by the infant is poor. the effect of intravenous magnesium on milk production is unknown. the developmental and health benefits to the neonate of breastfeeding should be considered along with the mother's clinical need for magnesium sulfate in 5% dextrose injection and any potential adverse effects on the breastfed infant from magnesium sulfate in 5% dextrose injection or from the underlying maternal condition. the safety and effectiveness of magnesium sulfate in 5% dextrose injection have been established for the prevention of eclampsia in adolescents with preeclampsia and the treatment of seizures and prevention of recurrent seizures in adolescents with eclampsia. dosing recommendation in pregnant adolescent patients are the same as for pregnant adult patients [see dosage and administration (2.2)] . magnesium is excreted solely by the kidneys. patients with severe renal impairment (urine output less than 100 ml per 4 hours) are at greater risk for increased magnesium concentrations that may lead to magnesium toxicity [see warnings and precautions (5.2) and clinical pharmacology (12.3)] . in patients with severe renal impairment, dosage reduction is recommended and the maximum recommended dosage is lower than patients with normal renal function [see dosage and administration (2.3)] .